277 related articles for article (PubMed ID: 33803438)
1. The Role of Antibiotic Resistant
Bagińska N; Cieślik M; Górski A; Jończyk-Matysiak E
Antibiotics (Basel); 2021 Mar; 10(3):. PubMed ID: 33803438
[No Abstract] [Full Text] [Related]
2. Bacteriophage therapy for
Bhargava K; Nath G; Dhameja N; Kumar R; Aseri GK; Jain N
Future Microbiol; 2023 Apr; 18():323-334. PubMed ID: 37140267
[TBL] [Abstract][Full Text] [Related]
3. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
4. Bacteriophage-based approach for treatment of urinary tract infections: a quick outlook.
Grygorcewicz B; Gliźniewicz M; Jabłońska J; Augustyniak A; Olszewska P; Wojciuk B; Miłek D; Serwin N; Czajkowski A; Cecerska-Heryć E; Rakoczy R; Cymbaluk-Płoska A
APMIS; 2024 Feb; 132(2):81-93. PubMed ID: 38031200
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of Microbial Factors of Healthcare-Associated Infections Including Multidrug-Resistant Pathogens and Antibiotic Consumption at the University Intensive Care Unit in Poland in the Years 2011-2018.
Litwin A; Fedorowicz O; Duszynska W
Int J Environ Res Public Health; 2020 Sep; 17(19):. PubMed ID: 32977435
[No Abstract] [Full Text] [Related]
6. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals.
Ibrahim S; Al-Saryi N; Al-Kadmy IMS; Aziz SN
Mol Biol Rep; 2021 Oct; 48(10):6987-6998. PubMed ID: 34460060
[TBL] [Abstract][Full Text] [Related]
7. Rescuing Tetracycline Class Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii Pulmonary Infection.
De Oliveira DMP; Forde BM; Phan MD; Steiner B; Zhang B; Zuegg J; El-Deeb IM; Li G; Keller N; Brouwer S; Harbison-Price N; Cork AJ; Bauer MJ; Alquethamy SF; Beatson SA; Roberts JA; Paterson DL; McEwan AG; Blaskovich MAT; Schembri MA; McDevitt CA; von Itzstein M; Walker MJ
mBio; 2022 Feb; 13(1):e0351721. PubMed ID: 35012353
[TBL] [Abstract][Full Text] [Related]
8. Environmental Phage-Based Cocktail and Antibiotic Combination Effects on
Grygorcewicz B; Wojciuk B; Roszak M; Łubowska N; Błażejczak P; Jursa-Kulesza J; Rakoczy R; Masiuk H; Dołęgowska B
Microb Drug Resist; 2021 Jan; 27(1):25-35. PubMed ID: 32543337
[TBL] [Abstract][Full Text] [Related]
9. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial.
Leitner L; Ujmajuridze A; Chanishvili N; Goderdzishvili M; Chkonia I; Rigvava S; Chkhotua A; Changashvili G; McCallin S; Schneider MP; Liechti MD; Mehnert U; Bachmann LM; Sybesma W; Kessler TM
Lancet Infect Dis; 2021 Mar; 21(3):427-436. PubMed ID: 32949500
[TBL] [Abstract][Full Text] [Related]
10. Virulence Potential and Treatment Options of Multidrug-Resistant (MDR)
Kumar S; Anwer R; Azzi A
Microorganisms; 2021 Oct; 9(10):. PubMed ID: 34683425
[No Abstract] [Full Text] [Related]
11. Bactericidal Synergism between Phage YC#06 and Antibiotics: a Combination Strategy to Target Multidrug-Resistant Acinetobacter baumannii
Luo J; Xie L; Liu M; Li Q; Wang P; Luo C
Microbiol Spectr; 2022 Aug; 10(4):e0009622. PubMed ID: 35736241
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
13. Multi-drug resistance of blood stream, urinary tract and surgical site nosocomial infections of Acinetobacter baumannii and Pseudomonas aeruginosa among patients hospitalized at Felegehiwot referral hospital, Northwest Ethiopia: a cross-sectional study.
Motbainor H; Bereded F; Mulu W
BMC Infect Dis; 2020 Jan; 20(1):92. PubMed ID: 32000693
[TBL] [Abstract][Full Text] [Related]
14. Ability of bacteriophage in resolving wound infection caused by multidrug-resistant Acinetobacter baumannii in uncontrolled diabetic rats.
Shivaswamy VC; Kalasuramath SB; Sadanand CK; Basavaraju AK; Ginnavaram V; Bille S; Ukken SS; Pushparaj UN
Microb Drug Resist; 2015 Apr; 21(2):171-7. PubMed ID: 25411824
[TBL] [Abstract][Full Text] [Related]
15. Phage Resistance Accompanies Reduced Fitness of Uropathogenic Escherichia coli in the Urinary Environment.
Zulk JJ; Clark JR; Ottinger S; Ballard MB; Mejia ME; Mercado-Evans V; Heckmann ER; Sanchez BC; Trautner BW; Maresso AW; Patras KA
mSphere; 2022 Aug; 7(4):e0034522. PubMed ID: 35920561
[TBL] [Abstract][Full Text] [Related]
16. Prevalence, etiology and antibiotic resistance patterns of community-acquired urinary tract infections in Dhaka, Bangladesh.
Islam MA; Islam MR; Khan R; Amin MB; Rahman M; Hossain MI; Ahmed D; Asaduzzaman M; Riley LW
PLoS One; 2022; 17(9):e0274423. PubMed ID: 36107878
[TBL] [Abstract][Full Text] [Related]
17. Development of Antimicrobial Therapy Methods to Overcome the Antibiotic Resistance of Acinetobacter baumannii.
Kisil OV; Efimenko TA; Gabrielyan NI; Efremenkova OV
Acta Naturae; 2020; 12(3):34-45. PubMed ID: 33173595
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.
Jain M; Sharma A; Sen MK; Rani V; Gaind R; Suri JC
Microb Pathog; 2019 Mar; 128():75-81. PubMed ID: 30562602
[TBL] [Abstract][Full Text] [Related]
19.
Gedefie A; Demsis W; Ashagrie M; Kassa Y; Tesfaye M; Tilahun M; Bisetegn H; Sahle Z
Infect Drug Resist; 2021; 14():3711-3719. PubMed ID: 34531666
[No Abstract] [Full Text] [Related]
20. Treatment of Acinetobacter infections.
Michalopoulos A; Falagas ME
Expert Opin Pharmacother; 2010 Apr; 11(5):779-88. PubMed ID: 20210684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
